Semax + Selank is a community- and commercially described two-peptide combination consisting of Semax and Selank. The individual peptides have separate human research histories, but the combination itself should not be treated as a standardized or clinically validated formulation.
Semax + Selank is best described as a two-peptide research pairing rather than a scientifically standardized formulation. Semax and Selank have distinct molecular origins and separate evidence bases.
The existence of a product or community label therefore does not establish that one particular ratio is the scientifically correct Semax + Selank formulation.
The basic stack contains two distinct peptides: Semax and Selank. Their individual scientific literature should be evaluated separately from evidence about the combination.
Semax is a synthetic heptapeptide derived from an ACTH-related peptide sequence. Its research literature includes neurological and cerebrovascular topics, particularly in Russian clinical research.
Selank is a synthetic heptapeptide related to tuftsin. Its published research includes anxiety-related clinical studies and investigations of neurochemical and immunological effects.
The pairing is generally discussed because the two peptides are associated with overlapping but non-identical neurological research themes. Semax is commonly discussed in relation to neuroprotection, neurological recovery and cognition, while Selank is commonly discussed in relation to anxiety, stress-related research and immunomodulatory signaling.
Semax has been evaluated in human research, particularly in Russian studies involving ischemic stroke and neurological recovery. For example, a 1997 clinical trial evaluated Semax in 30 patients with acute hemispheric ischemic stroke compared with a conventional-treatment control group. :contentReference[oaicite:2]{index=2}
A later study involving 110 patients after ischemic stroke examined Semax in relation to BDNF levels, motor performance and Barthel Index outcomes. The authors reported increased BDNF levels and improvements in some measured outcomes, but the study should be interpreted within its specific population and design rather than generalized to healthy people or to the Semax + Selank combination. :contentReference[oaicite:3]{index=3}
Human studies of Semax exist, particularly in Russian neurological research.
Much of the evidence base has not been independently replicated across modern Western clinical systems.
Semax findings cannot be used as proof that Semax + Selank is effective or safe.
Selank also has a human research record. A randomized controlled study published in 2008 evaluated 62 patients with generalized anxiety disorder and neurasthenia, comparing Selank with medazepam. The study reported anxiolytic effects and additional changes in fatigue-related measures. :contentReference[oaicite:4]{index=4}
Other research has examined Selank in anxiety disorders and investigated immunomodulatory effects. These studies provide information about Selank as an individual research compound; they do not establish the performance of a combined Semax + Selank preparation. :contentReference[oaicite:5]{index=5}
The important distinction is that Semax and Selank have been studied individually, and both appeared in the same 2020 functional-connectivity research project. However, participants received either Semax, Selank, or placebo rather than both peptides together. :contentReference[oaicite:6]{index=6}
Separate human research exists for Semax, including neurological and stroke-related research.
Separate human research exists for Selank, including anxiety-related studies.
A 2020 study evaluated effects of each peptide and placebo in separate groups.
No combination arm means the study cannot establish combination efficacy, safety, optimal ratio or interaction.
There is no single universally standardized Semax + Selank mass ratio that should be assumed for every research product. Commercially documented products can use different concentrations and ratios.
| Formulation context | Example documented composition | Interpretation |
|---|---|---|
| Equal-mass research blend | 10 mg Semax + 10 mg Selank | Example of a 1:1 mass ratio; not a universal standard. |
| Commercial 50:50 formulation | Products have been documented using equal Semax/Selank proportions. | Commercial formulation evidence does not establish clinical standardization. |
| Separate-vial research | Semax and Selank supplied independently | Allows the compounds to be evaluated separately rather than assuming a fixed blend. |
For a multi-component vial, the concentration of each peptide is calculated independently using that peptide's own mass divided by the final liquid volume. The same final volume applies to both components, but the masses remain separate.
Component concentration (mg/mL) = component mass (mg) ÷ final liquid volume (mL)| Component | 1 mL final volume | 2 mL final volume | 3 mL final volume | 5 mL final volume |
|---|---|---|---|---|
| Semax — 10 mg | 10 mg/mL | 5 mg/mL | 3.33 mg/mL | 2 mg/mL |
| Selank — 10 mg | 10 mg/mL | 5 mg/mL | 3.33 mg/mL | 2 mg/mL |
With 10 mg Semax and 10 mg Selank in a final volume of 2 mL:
Semax = 10 mg ÷ 2 mL = 5 mg/mL
Selank = 10 mg ÷ 2 mL = 5 mg/mL
The total peptide mass is 20 mg, but it is incorrect to describe each component as 20 mg/mL. The 10 mg Semax and 10 mg Selank must each be divided by the final volume independently.
The same principle applies when the two components are not present at a 1:1 ratio. For example, a hypothetical vial containing 10 mg Semax and 5 mg Selank at a final volume of 5 mL would produce:
| Component | Mass | Final volume | Calculated concentration |
|---|---|---|---|
| Semax | 10 mg | 5 mL | 2 mg/mL |
| Selank | 5 mg | 5 mL | 1 mg/mL |
There is no evidence-based universal BAC-water volume for a Semax + Selank combination because formulations vary and the combination has not been clinically standardized. A BAC-water volume can be evaluated mathematically only after the exact mass of each component and the intended final volume are known.
Example: if a vial contains 10 mg Semax and 10 mg Selank, a 5 mL final volume mathematically produces 2 mg/mL Semax and 2 mg/mL Selank. This is a concentration calculation, not a clinical administration instruction.
Use the BacScience Universal BAC Water Calculator for single-compound concentration mathematics. For multi-component formulations, calculate each ingredient separately rather than combining the peptide masses.
Open BAC Water Calculator| Question | Evidence status | What can responsibly be concluded? |
|---|---|---|
| Has Semax been studied in humans? | Yes | Individual human research exists. |
| Has Selank been studied in humans? | Yes | Individual human research exists. |
| Were Semax and Selank studied in the same research project? | Yes | A 2020 fMRI study evaluated separate Semax and Selank groups. |
| Were both administered to the same participants? | No | The study did not establish combination effects. |
| Is there a validated universal Semax:Selank ratio? | No | Commercial formulations can vary. |
| Does individual evidence prove stack efficacy? | No | Individual-component evidence cannot establish combination efficacy. |
Regulatory status varies by country and formulation. Semax and Selank should not be presented as FDA-approved therapies in the United States. FDA materials discussing bulk substances for compounding identify Semax and Selank acetate among substances for which potential safety concerns have been identified. :contentReference[oaicite:7]{index=7}
For a multi-component formulation, an additional question exists: whether the components remain chemically and physically compatible when placed into the same solution. The absence of a clinical combination trial also means that the interaction profile of the exact blend is not established.
It is a community and commercial term for a combination of Semax and Selank. It is not a universally standardized clinical formulation.
No. They are chemically distinct synthetic heptapeptides with different sequences and separate research histories.
A 2020 human fMRI study examined both compounds, but participants received either Semax, Selank or placebo rather than both peptides together. Therefore it was not a combination-treatment trial.
No universal formulation should be assumed. Commercial and research products may use different masses, ratios, concentrations and presentation formats.
No. Evidence for an individual component cannot establish efficacy, safety or synergy of a combination.
No. Selank's individual research must remain separate from evidence for the combined formulation.
Calculate each component independently: component mass in mg divided by the final liquid volume in mL.
They may be added to determine total peptide mass, but the total should not be used as the concentration of either individual component.
Mathematically, yes. If the component masses stay constant while the final volume increases, the concentration of each component decreases.
No universally validated ratio was identified. A 1:1 mass ratio may appear in commercial contexts, but commercial prevalence is not equivalent to clinical validation.
Semax + Selank should not be described as an FDA-approved combination therapy. FDA materials have also identified potential safety concerns involving Semax and Selank acetate in compounding contexts.
Last reviewed: September 11, 2026
Research-use educational reference. This page does not provide diagnosis, treatment, dosing, administration, or medical-use instructions.